caseism

Intellikine: Build-to-Sell in Biotech Case Solution & Answer

The case study is an example of Intellikine a biotechnology company, where the management team, founders and investors sold the company at a relatively early stage of development of the company. In early 2012, Troy Wilson, CEO of the company sold Intellikine Millennium: The Takeda Oncology Company, Takeda’s business unit responsible for global oncology strategy and development. The agreement was provided $ 310 million ($ 190 million Millennium pay in advance with a $ 120 million depend on the phases of clinical development). In 2011, the team had advanced Intellikine three programs in human clinical trials. The key question for students is whether Wilson and his team have sold the business too soon or not. Different views and business strategy and execution are provided in the case study to allow students to have a meaningful discussion on every aspect of the issue.
by
Larry Lasky
Source: UCB – Haas School of Business
11 pages.
Release Date: February 1, 2013. Prod #: B5763-PDF-ENG
Intellikine: Build-to-sales solution in the Biotech case

Share This

LOOK FOR A FREE CASE STUDY SOLUTION

JUST REGISTER NOW AND GET 50% OFF ON EACH CASE STUDY